Summary
Quinidine, procainamide and disopyramide are antiarrhythmic drugs in the class 1A category. These drugs have a low toxic to therapeutic ratio, and their use is associated with a number of serious adverse effects during long term therapy and life-threatening sequelae following acute overdose.
Class 1A agents inhibit the fast inward sodium current and decrease the maximum rate of rise and amplitude of the cardiac action potential. Prolonged Q-T interval and, to a lesser extent, QRS duration may be observed at therapeutic concentrations of quinidine. With increasing plasma concentrations, progressive depression of automaticity and conduction velocity occur. ‘Quinidine syncope’ (a transient loss of consciousness due to paroxysmal ventricular tachycardia, frequently of the torsade de pointes type) occurs with therapeutic dosing, often in the first few days of therapy. Extracardiac adverse effects of quinidine include potentially intolerable gastrointestinal effects and hypersensitivity reactions such as fever, rash, blood dyscrasias and hepatitis.
Procainamide produces electrophysiological changes that are similar to those of quinidine, although Q-T interval prolongation with the former is less pronounced at therapeutic concentrations. Hypersensitivity reactions including fever, rash and (more seriously) agranulocytosis are associated with procainamide, and a frequent adverse effect requiring cessation of therapy is the development of systemic lupus erythematosus.
Of the 3 drugs, disopyramide has the most pronounced negative inotropic effects, which are especially significant in patients with pre-existing left ventricular dysfunction. As with quinidine, unexpected ‘disopyramide syncope’ at therapeutic concentrations has been described. Anticholinergic side effects are common with this drug and may require cessation of therapy. Disopyramide therapy may unpredictably induce severe hypoglycaemia.
Severe intoxication with the class 1A agents may result from acute accidental or intentional overdose, or from accumulation of the drugs during long term therapy. Acute overdose can result in severe disturbances of cardiac conduction and hypotension, frequently accompanied by central nervous system toxicity. Decreased renal function can cause significant accumulation of procainamide and its active metabolite acecainide (N-acetyl-procainamide), resulting in severe intoxication. Mild to moderate renal dysfunction is less likely to lead to quinidine or disopyramide intoxication, unless renal failure is severe or concurrent hepatic dysfunction is present.
Management of acute intoxication with class 1A drugs includes gut decontamination with provision of respiratory support and treatment of seizures as needed. Hypertonic sodium bicarbonate, by antagonising the inhibitory effect of quinidine on sodium conductance, may reverse many or all manifestations of cardiovascular toxicity. Isoprenaline (isoproterenol) and cardiac pacing are useful for bradyarrhythmias; magnesium sulfate, isoprenaline and overdrive pacing should be used to treat polymorphous ventricular tachycardia. Extracorporeal drug removal techniques, such as haemoperfusion or haemodialysis, are of little benefit for quinidine but are likely to be useful for severe procainamide, acecainide and disopyramide intoxications, particularly in the presence of renal insufficiency.
Similar content being viewed by others
References
Agudelo CA, Wise CM, Lyles MF. Pure red cell aplasia in procainamide induced systemic lupus erythematosus: report and review of the literature. Journal of Rheumatology 15: 1431–1432, 1988
Anderson JL, Mason JW. Successful treatment by overdrive pacing of recurrent quinidine syncope due to ventricular tachycardia. American Journal of Medicine 64: 715–718, 1978
Arimori K, Kawano H, Nakano M. Gastrointestinal dialysis of disopyramide in healthy subjects. International Journal of Clinical Pharmacology, Therapy and Toxicology 27 (6): 280–284, 1989
Asherson RA, Zulman J, Hughes GRV. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Annals of the Rheumatic Diseases 48: 232–235, 1989
Atkinson AJ, Krumlovsky FA, Huang CM, del Greco F. Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. Clinical Pharmacology and Therapeutics 20: 585–592, 1976
Atkinson AJ, Lee WK, Quinn ML, Kushner W, Nevin MJ, et al. Dose-ranging trial of N-acetylproeainamide in patients with premature ventricular contractions. Clinical Pharmacology and Therapeutics 21: 575–587, 1977
Atkinson AJ, Ruo TI, Piergies AA. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Angiology 39: 655–667, 1988
Au PK, Bhandari AK, Bream R, Schreck D, Siddiqi R, et al. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia. Journal of the American College of Cardiology 9: 389–397, 1987
Bailey DJ. Cardiotoxic effects of quinidine and their treatment. Archives of Internal Medicine 105: 13–22, 1960
Barzel US. Quinidine sulfate induced hypoplastic anemia and agranulocytosis. Journal of the American Medical Association 201: 325–327, 1967
Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, et al. Torsade de pointes due to quinidine: observations in 31 patients. American Heart Journal 107: 425–430, 1984
Bauman JL, Gallastegui J, Strasberg B, Swiryn S, Hoff J, et al. Long-term therapy with disopyramide phosphate: side effects and effectiveness. American Heart Journal 111: 654–660, 1986
Bedell SE, Kang JL. Leukocytosis and left shift associated with quinidine fever. American Journal of Medicine 77: 345–346, 1984
Befeler B, Castellanos A, Wells DE. Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate. American Journal of Cardiology 35: 282–287, 1975
Bellet S, Hamden G, Somlyo A. Reversal of the cardiotoxic effects of quinidine by molar sodium lactate. Clinical Research 6: 226–230, 1958
Bellet S, Hamden G, Somlyo A, Lara R. The reversal of cardiotoxic effects of quinidine by molar sodium lactate: an experimental study. American Journal of the Medical Sciences 237: 165–176, 1959
Benowitz NL. Quinide, procainamide and disopyramide. In Haddad & Winchester (Eds) Clinical management of poisoning and drug overdose, p.854, W.B. Saunders Co., Philadelphia, 1983
Benowitz NL, Goldschlager N. Cardiac disturbances in the toxicologic patient. In Haddad & Winchester (Eds) Clinical management of poisoning and drug overdose, p.87, W.B. Saunders Co., Philadelphia, 1983
Bigger JT, Heissenbuttel RH. The use of procainamide and lidocaine in the treatment of cardiac arrhythmias. Progress in Cardiovascular Diseases 11: 515–534, 1969
Bonde J, Graudal NA, Pederson LE, Balslv S, Angelo HR, et al. Kinetics of disopyramide in decreased hepatic function. European Journal of Clinical Pharmacology 31: 73–77, 1986
Bourliere M, Bernuau J, Rueff B, Benhamou JP. Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman. Journal of Hepatology 6: 214–216, 1988
Braden GL, Fitzgibbons JP, Germain MJ, Ledewitz HM. Hemoperfusion for treatment of N-acetylprocainamide intoxication. Annals of Internal Medicine 105: 64–65, 1986
Bramlet DA, Posalaky Z, Olson R. Granulomatous hepatitis as a manifestation of quinidine hypersensitivity. Archives of Internal Medicine 140: 395–397, 1980
Brandfonbrenner M, Kronholm J, Jones HR. The effect of serum potassium concentration on quinidine toxicity. Journal of Pharmacology and Experimental Therapeutics 154: 250–254, 1966
Brogden RN, Todd PA. Disopyramide: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs 34: 151–187, 1987
Brugada J, Sassine A, Escande D, Masse C, Puech P. Effects of quinidine on ventricular repolarization. European Heart Journal 8: 1340–1345, 1987
Bryson SM, Whiting B, Lawrence JR. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. British Journal of Clinical Pharmacology 6: 409–419, 1978
Capparelli EV, DiPersio DM, Zhao H, Kluger J, Chow MS. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. Journal of Clinical Pharmacology 28: 306–311, 1988
Cascio WE, Foster JR, Buchanan JW, Johnson TA, Gettes LS. Enhancement of procainamide-induced rate-dependent conduction slowing by elevated myocardial extracellular potassium concentration in vivo. Circulation 76: 1380–1387, 1987
Cheng TO, Sutton GC, Swisher WP, Sutton D. Effect of quinidine on the ventricular complex of the electrocardiogram with special reference to the duration of the Q-T interval. American Heart Journal 51: 417–444, 1956
Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Progress in Cardiovascular Diseases 20: 151–163, 1977
Cohen MG, Kevat S, Prowse MV, Ahern MJ. Two distinct quinidine-induced rheumatic syndromes. Annals of Internal Medicine 108: 369–371, 1988
Connolly SJ, Kates RE. Clinical pharmacokinetics of N-acetylprocainamide. Clinical Pharmacokinetics 7: 206–220, 1982
Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation 55: 1–7, 1977
Cox AR, West TC. Sodium lactate reversal of quinidine effect studied in rabbit atria by the microelectrode technique. Journal of Pharmacology and Experimental Therapeutics 131: 212–222, 1961
Croxson MS, Shaw DW, Henley PG, Gabriel HD. Disopyramideinduced hypoglycaemia and increased serum insulin. New Zealand Medical Journal 100: 407–408, 1987
Cunningham JL, Shen DD, Shudo I. Azarnoff DI. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clinical Pharmacokinetics 2: 373–383, 1977
Data JL, Wilkinson GR, Nies AS. Interaction of quinidine with anticonvulsant drugs. New England Journal of Medicine 294: 699–702, 1976
de Azevedo IM, Watanabe Y, Dreifus LS. Electrophysiologic antagonism of quinidine and bretylium tosylate. American Journal of Cardiology 33: 633–638, 1974
Deleu D, Schmedding E. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases. British Medical Journal. 294: 1001–1002, 1987
Desai JM, Scheinman MM, Hirschfeld D, Gonzalez R, Peters RW. Cardiovascular collapse associated with disopyramide therapy. Chest 79: 545–551, 1981
Dhurandhar RW, Nademanee K, Goldman AM. Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases. Heart and Lung 7: 783–787, 1978
Domoto DT, Brown WW, Bruggensmith P. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration. Annals of Internal Medicine 106: 550–552, 1987
Drachman DA, Skom JH. Procainamide — a hazard in myasthenia gravis. Archives of Neurology 13: 316–320, 1965
Drayer DE, Lowenthal DT, Restivo KM, Schwartz A, Cook CE, et al. Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function. Clinical Pharmacology and Therapeutics 24: 31–39, 1978
Echizen H, Salma S, Umeda N, Ishizaki T. Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome. Clinical Pharmacology and Therapeutics 40: 274–280, 1986
Edwards DJ, Lavoie R, Beckman H, Blevins R, Rubenfire M. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. Clinical Pharmacology and Therapeutics 41: 68–73, 1987
El-Sherif N, Bekheit S, Henkin R. Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations. Journal of the American College of Cardiology 14: 252–257, 1989
Elson J, Strong JM, Lee WK. Antiarrhythmic potency of N-acetylprocainamide. Clinical Pharmacology and Therapeutics 17: 134–140, 1975
Finnegan TRL, Trounce JR. Depression of the heart by quinidine and its treatment. British Heart Journal 16: 341–350, 1954
Foley RE, Parnado EA. Drug fever of quinidine. Report of a case and review of the literature. Lahey Clinic Foundation Bulletin 15: 49–52, 1966
Freed JS, Reiner MA. Septic complications of procainamide-induced agranulocytosis: report of two cases. Mount Sinai Journal of Medicine 55: 194–197, 1988
Galeazzi RL, Sheiner LB, Lockwood T, Benet LZ. The renal elimination of procainamide. Clinical Pharmacology and Therapeutics 19: 55–62, 1976
Garfinkel D, Mamelok RD, Blaschke TF. Altered therapeutic range for quinidine after myocardial infarction and cardiac surgery. Annals of Internal Medicine 107: 48–50, 1987
Gay RJ, Brown DF. Pacemaker failure due to procainamide toxicity. American Journal of Cardiology 34: 728–732, 1974
Geltner D, Chajek T, Rubinger D. Quinidine hypersensitivity and liver involvement: a survey of 32 patients. Gastroenterology 70: 650–652, 1976
Gerhardt RE, Knouss RF, Thyrum PT, Luchi RJ, Morris JJ. Quinidine excretion in aciduria and alkaluria. Annals of Internal Medicine 71: 927–934, 1969
Gertler MM, Kream J, Hylin JW, Robinson H, Neidle EG. Effects of digoxin and quinidine on intracellular electrolytes of the rabbit heart. Experimental Biology and Medicine 92: 629–635, 1956
Giannone L, Kugler JW, Krantz SB. Pure red cell aplasia associated with administration of sustained-release procainamide. Archives of Internal Medicine 147: 1179–1180, 1987
Gibson TP, Lowenthal DT, Nelson HA, Briggs WA. Elimination of procainamide in end stage renal failure. Clinical Pharmacology and Therapeutics 17: 321–329, 1975
Gosselin B, Mathieu D, Chopoin C, Wattel F, Dupuis B, et al. Acute intoxication with disopyramide: clinical and experimental study by hemoperfusion on Amberlite XAD 4 Resin. Clinical Toxicology 17: 439–440, 1980
Gottsegen G, Ostor E. Prevention of the cardiotoxic effect of quinidine by isoproterenol. American Heart Journal 65: 102–109, 1963
Grant AM, Marshall RJ, Ankier SI. Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle. European Journal of Pharmacology 49: 389–394, 1978
Grant AO, Trantham JL, Brown KK, Strauss HC. pH-Dependent effects of quinidine on the kinetics of dV/dtmax in guinea pig ventricular myocardium. Circulation Research 50: 210–217, 1982
Grayzel J, Angeles J. Sino-atrial block in man provoked by quinidine. Journal of Electrocardiology 5: 289–294, 1972
Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, MacLaughlin DS, et al. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. Journal of Pharmacology and Experimental Therapeutics 202: 365–378, 1977
Haapanen EJ, Pellinen TJ. Hemoperfusion in quinidine intoxication. Acta Medica Scandinavia 210: 515–516, 1981
Hall CD, Malouf N. Skeletal muscle weakness resulting from quinidine ingestion. Southern Medical Journal 80: 403–404, 1987
Hall K, Meatherall B, Krahn J, Penner B, Rabson JL. Clearance of quinidine during peritoneal dialysis. American Heart Journal 104: 646–647, 1982
Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 388–391, 1988
Hayler AM, Holt DW, Volans GN. Fatal overdosage with disopyramide. Lancet 1: 968–969, 1978
Hayler AM, Medd RK, Holt DW, O’Keeffe BD. Experimental disopyramide poisoning: treatment by cardiovascular support and with charcoal hemoperfusion. Journal of Pharmacology and Experimental Therapeutics 211: 491–495, 1979
Hemmermeister KE, Boerth RC, Warbasse JR. The comparative inotropic effects of six clinically used antiarrhythmic agents. American Heart Journal 84: 643–652, 1972
Henningsen NC, Cederberg A, Hanson A, Johansson BW. Effects of long-term treatment with procaine amide: a prospective study with special regard to ANF and SLE in fast and slow acetylators. Acta Medica Scandinavica 198: 475–482, 1975
Hey EB, Makous N, Vander Veer JB. Fever and chills as reaction to procainamide hydrochloride therapy. Archives of Internal Medicine 116: 544–546, 1965
Hinderung PH, Garrett ER. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. Journal of Pharmacokinetics and Biopharmaceutics 4: 199–230, 1976
Hoffman BF, Rosen MR, Wit AL. Electrophysiology and pharmacology of cardiac arrhythmias: VII. Cardiac effects of quinidine and procaine amide B. American Heart Journal 90: 117–122, 1975
Hoffmeister HM, Hepp A, Seipel L. Negative inotropic effect of class-1-antiarrhythmic drugs: comparison of flecainide with disopyramide and quinidine. European Heart Journal 8: 1126–1132, 1987
Holt DW, O’Keeffe B, Marshall CB, Helliwell M, Hayler AM, et al. Successful management of serious disopyramide poisoning. Postgraduate Medical Journal 56: 256–260, 1980
Honerjager P. The contribution of Na channel block to the negative inotropic effect of antiarrhythmic drugs. Basic Research in Cardiology 81 (Suppl. 1): 33–37, 1986
Horn JR, Hughes ML. Disopyramide dialysability. Lancet 2: 214, 1978
Hoyt RE. Severe neutropenia due to sustained-release procainamide. Southern Medical Journal 80: 1196–1197, 1987
Hutchison A, Kilham H. Fatal overdose of disopyramide in a child. Medical Journal of Australia 2: 335–336, 1978
Jaeger A, Sauder, Ph, Tempe JD, Mantz JM. Intoxications aigües par le disopyramide. Nouvelle Presse Medicale 10: 2883–2887, 1981
Javaheri S, Logemann TN, Corser BC, Guerra LF, Means E. Diaphragmatic paralysis. American Journal of Medicine 86: 623–624, 1989
Jensen G, Sigurd B, Uhrenholt A. Haemodynamic effects of intravenous disopyramide in heart failure. European Journal of Clinical Pharmacology 8: 167–173, 1975
Josephson MA, Schwab M, Coyle K, Singh BN. Effects of intravenous N-acetylprocainamide on hemodynamics and left ventricular function in man. American Heart Journal 113: 952–957, 1987
Josephson ME, Seides SF, Batsford WP, Weisfogel GM, Akhtar M, et al. The electrophysiological effects of intramuscular quinidine on the atrioventricular conducting system in man. American Heart Journal 87: 55–64, 1974
Kambam JR, Franks JJ, Naukam R, Sastry BVR. Effect of quinidine on plasma cholinesterase activity and succinylcholine neuromuscular blockade. Anesthesiology 67: 858–860, 1987a
Kambam JR, Franks JJ, Smith BE. Inhibitory effect of quinidine on plasma pseudocholinesterase activity in pregnant women. American Journal of Obstetrics and Gynecology 157: 897–899, 1987b
Kambam JR, Naukam RJ, Sastry BV. The effect of procainamide on plasma cholinesterase activity. Canadian Journal of Anaesthesia 34: 579–581, 1987c
Kapil RP, Axelson JE, Mansfield IL, Edwards DJ, McErlane B, et al. Disopyramide pharmacokinetics and metabolism: effect of inducers. British Journal of Clinical Pharmacology 24: 781–791, 1987
Kaplinsky E, Yahini JH, Barzilai J, Neufeld HN. Quinidine syncope; report of a case successfully treated with lidocaine. Chest 62: 764–766, 1972
Karlsson E. Clinical pharmacokinetics of procainamide. Clinical Pharmacokinetics 3: 97–107, 1978
Kaseda S, Gilmour RF, Zipes DP. Depressant effect of magnesium on early afterdepolarizations and triggered activity induced by cesium, quinidine and 4-aminopyridine in canine cardiac Purkinje fibers. American Heart Journal 118: 458–466, 1989
Kavanagh KM, Wyse DG, Mitchell LB, Gillhooly T, Gillis AM, et al. Contribution of quinidine metabolites to electrophysiologic responses in human subjects. Clinical Pharmacology and Therapeutics 46: 352–358, 1989
Kerr F, Kenoyer G, Bilitch M. Quinidine overdose. Neurological and cardiovascular toxicity in a normal person. British Heart Journal 33: 629–631, 1971
Kessler KM, Kayden DS, Estes DM, Koslovskis PL, Sequeira R, et al. Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. Journal of the American College of Cardiology 7: 1131–1139, 1986
Kessler KM, Kissane B, Cassidy J, Pefkaros KC, Kozlovskis P, et al. Dynamic variability of binding of antiarrhythmic drugs during the evolution of acute myocardial infarction. Circulation 70: 472–478, 1984
Kessler KM, Lowenthal DT, Warner H, Gibson T, Briggs W, et al. Quinidine elimination in patients with congestive heart failure or poor renal function. New England Journal of Medicine 290: 706–709, 1974
Killeen AA, Bowers LD. Fetal supraventricular tachycardia treated with high-dose quinidine: toxicity associated with marked elevation of the metabolite, 3(S)-3-hydroxyquinidine. Obstetrics and Gynecology 70: 445–449, 1987
Kluger J, Drayer DE, Reidenberg MM. Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome. Annals of Internal Medicine 95: 18–23, 1981
Knobler H, Levij IS, Gavish D, Chajek-Shaul T. Quinidine-induced hepatitis. A common and reversible hypersensitivity reaction. Archives of Internal Medicine 146: 526–528, 1986
Koch MJ, Seeff LB, Crumley CE, Rabin L, Burns WA. Quinidine hepatotoxicity. A report of a case and review of the literature. Gastroenterology 70: 1136–1140, 1976
Koch-Weser J. Pharmacokinetics of procainamide in man. Annals of the New York Academy of Sciences 179: 370–382, 1971
Koch-Weser J, Klein SW. Procainamide dosage schedules, plasma concentrations and clinical effects. Journal of the American Medical Association 215: 1454–1460, 1971
Konishi T, Kadoya M, Ikeguchi S, Sakai K, Tamamura T, et al. Combined effect of disopyramide and bethanechol: use of bethanechol to prevent anticholinergic side effects of disopyramide without reduction of antiarrhythmic efficacy. Journal of Cardiovascular Pharmacology 14: 341–350, 1989
Kosoglou T, Rocci ML, Vlasses PH. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clinical Pharmacology and Therapeutics 44: 467–477, 1988
Kosowsky BD, Taylor J, Lown B, Ritchie RF. Long-term use of procaine amide following acute myocardial infarction. Circulation 47: 1204–1210, 1973
Koster RW, Wellens HJJ. Quinidine-induced ventricular flutter and fibrillation without digitalis therapy. American Journal of Cardiology 38: 519–523, 1976
Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. International Journal of Clinical Pharmacology Therapy and Toxicology 26: 118–121, 1988
Landmark K, Bredesen JE, Thaulow E, Simonsen S, Amlie JP. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. European Journal of Clinical Pharmacology 19: 187–192, 1981
Lertora JL, Glock D, Stec GP, Atkinson AJ, Goldberg LI. Effects of N-acetylprocainamide and procainamide on myocardial contractile force, heart rate, and blood pressure. Proceedings of the Society for Experimental Biology and Medicine 161: 332–336, 1979
Lewis CA, Boheimer N, Rose P, Jackson G. Myopathy after short term administration of procainamide. British Medical Journal 292: 593–594, 1986
List AF, Doll DC. Thrombosis associated with procainamide-induced lupus anticoagulant. Acta Haematologica 82: 50–52, 1989
Lo KS, Gantz KB, Stetson PL, Lucchesi BR, Pitt B. Disopyramide-induced ventricular tachycardia. Archives of Internal Medicine 140: 413–414, 1980
Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation 44: 130–142, 1971
Makers PB, Salem AG. Agranulocytosis secondary to extendedrelease procainamide: a case report and review of the literature. South Dakota Journal of Medicine 40: 7–10, 1987
Manion CV, Lalka D, Baer DT. Absorption kinetics of procainamide in humans. Journal of Pharmaceutical Sciences 66: 981–984, 1977
Mason JW, Winkle RA, Ingels NB, Daughters GT, Harrison DC, et al. Hemodynamic effects of intravenously administered quinidine on the transplanted human heart. American Journal of Cardiology 40: 99–104, 1977
McNulty RM, Lazor JA, Sketch M. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. Clinical Pharmacy 8: 222–225, 1989
Meltzer RS, Robert EW, McMorrow M, Martin RP. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity. American Journal of Cardiology 42: 1049–1052, 1978
Miller B, Skupin A, Rubenfire M, Bigman O. Respiratory failure produced by severe procainamide intoxication in a patient with preexisting peripheral neuropathy caused by amiodarone. Chest 94: 663–664, 1988
Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystowsky EN. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. New England Journal of Medicine 319: 257–262, 1988
Morady F, Scheinman MM, Desai J. Disopyramide. Annals of Internal Medicine 96: 337–343, 1982
Murphy WG, Kelton JG. Idiosyncratic drug-induced thrombocytopenia. Current Studies in Hematology and Blood Transfusion 54: 71–88, 1988
Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, et al. Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas. Metabolism 38: 179–183, 1989
Nappi JM, Dhanani S, Lovejoy JR, VanderArk C. Severe hypoglycemia associated with disopyramide. Western Journal of Medicine 138: 95–97, 1983
Nattel S, Elharrar V, Zipes DP, Bailey JC. pH-Dependent electrophysiological effects of quinidine and lidocaine on canine cardiac Purkinje fibers. Circulation Research 48: 55–61, 1981
Nawrath H. Action potential, membrane currents and force of contraction in mammalian heart muscle fibers treated with quinidine. Journal of Pharmacology and Experimental Therapeutics 216: 176–182, 1981
Nguyen KPV, Thomsen G, Liem B, Swerdlow CD, Franz MR. N-acetylprocainamide, torsades de pointes and hemodialysis. Annals of Internal Medicine 104: 283–284, 1986a
Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 74: 340–349, 1986b
Nicholson WJ, Martin CE, Gracey JG, Knoch HR. Disopyramide-induced ventricular fibrillation. American Journal of Cardiology 43: 1053–1055, 1979
Nickel ST, Thibaudeau Y. Quinidine intoxication treated by isoproterenol (isuprel). Canadian Medical Association Journal 85: 81–83, 1961
Nightingale J, Jappi JM. Effect of phenytoin on serum disopyramide concentrations. Clinical Pharmacy 6: 46–50, 1987
Nolan MT, Prichard JS. Non-fatal overdose with disopyramide. Irish Medical Journal 77: 209, 1984
Ochs HR, Greenblatt DJ, Wood E. Clinical pharmacokinetics of quinidine. Clinical Pharmacokinetics 5: 150–168, 1980
Oh SJ, Elmore RS, Sarala PK, Kuba T. Procainamide-induced myasthenia-like syndrome. Muscle and Nerve 9: 670–672, 1986
Pariente EA, Maitre F, Marchand JP. Hepatitis caused by quinidine. Study of a case and review of the literature. Gastroenterology and Clinical Biology 10: 255–258, 1986
Piergies AA, Ruo TI, Jansyn EM, Belknap SM, Atkinson AJ. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clinical Pharmacology and Therapeutics 42: 107–112, 1987
Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure caused by oral disopyramide. New England Journal of Medicine 302: 614–617, 1980
Prendergast MD, Nasca TJ. Anticholinergic syndrome with procainamide toxicity. Journal of the American Medical Association 251: 2926–2927, 1984
Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. American Journal of Medicine 86: 465–466, 1989
Raja R, Kramer M, Alvis R, Goldstein S, De Los Angeles A. Resin hemoperfusion for severe N-acetylprocainamide toxicity in patients with renal failure. Transactions of the American Society for Articial Internal Organs 30: 18–20, 1984
Reid DM, Shulman NR. Drug purpura due to surreptitious quinidine intake. Annals of Internal Medicine 108: 206–208, 1988
Reidenberg MM, Drayer DE. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus. Angiology 37: 968–971, 1986
Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation of procainamide in man. Clinical Pharmacology and Therapeutics 17: 722–730, 1975
Reimold EW, Reynolds WJ, Fixier DE, McElroy L. Use of hemodialysis in the treatment of quinidine poisoning. Pediatrics 52: 95–99, 1973
Reiter MJ, Higgins SL, Payne AG, Mann DE. Effects of quinidine versus procainamide on the QT interval. American Journal of Cardiology 58: 512–516, 1986
Reynolds EW, VanderArk CR. Quinidine syncope and the delayed repolarization syndromes. Modern Concepts of Cardiovascular Disease 45: 177–122, 1976
Richardson B, Cornacchia E, Golbus J, Maybaum J, Strahler J, et al. N-acetylprocainamide is a less potent inducer of T cell autoreactivity than procainamide. Arthritis and Rheumatism 31: 995–999, 1988
Rizos I, Brachmann J, Lengfelder W, Schmitt C, von Olshausen K, et al. Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia. European Heart Journal 8: 154–163, 1987
Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. Journal of the American College of Cardiology 8: 73A–78A, 1986a
Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. American Heart Journal 111: 1088–1093, 1986b
Rodvold KA, Paloucek FP, Jung D, Gallastegui J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Therapeutic Drug Monitoring 9: 378–383, 1987
Romankiewicz JA, Reidenberg M, Drayer D, Franklin JE. The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: an approach to control quinidine-induced diarrhea. American Heart Journal 96: 518–520, 1978
Rosansky SJ, Brady ME. Procainamide toxicity in a patient with acute renal failure. American Journal of Kidney Diseases 7: 502–506, 1986
Rosketh R, Storstein O. Quinidine therapy of chronic auricular fibrillation. Archives of Internal Medicine 111: 184–190, 1963
Rubin RL, Nusinow SR, Johnson AD, Rubenson DS, Curd JG, et al. Serologic changes during induction of lupus-like disease by procainamide. American Journal of Medicine 80: 999–1002, 1986
Saleh MN, Dhodaphar N, Allen K, LoBuglio AF. Quinidine-induced immune thrombocytopenia. Henry Ford Hospital Medical Journal 37: 28–32, 1989
Sasyniuk BI, Jhamandas V. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate. Journal of Pharmacology and Experimental Therapeutics 231: 387–394, 1984
Sathyavagiswaran L. Fatal disopyramide intoxication from suicidal/accidental overdose. Journal of Forensic Sciences 32: 1813–1818, 1987
Schmid PG, Nelson LD, Heistad DD, Mark AL, Abboud FM. Vascular effects of procaine amide in the dog. Predominance of the inhibitory effect on ganglionic transmission. Circulation Research 35: 948–960, 1974b
Schmid PG, Nelson LD, Mark AL, Heistad DD, Abboud FM. Inhibition of adrenergic vasoconstriction by quinidine. Journal of Pharmacology and Experimental Therapeutics 188: 124–134, 1974a
Schwartz AB, Klausner SC, Yee S. Cerebellar ataxia due to procainamide toxicity. Archives of Internal Medicine 144: 2260–2261, 1984
Selzer AH, Wray AW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30: 17–26, 1964
Sevka MJ, Matthews SJ, Nightingale CH. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis. Clinical Pharmacology and Therapeutics 29: 322–326, 1981
Shields AF, Berenson JA. Procainamide-associated pancytopenia. American Journal of Hematology 27: 299–301, 1988
Shub C, Gay GT, Sidell PM, Brennan LA. The management of acute quinidine intoxication. Chest 73: 173–178, 1978
Sica DA, Yonce C, Small R, Cefali E, Harford A, et al. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 59–64, 1988
Slater W, Lampert S, Podrid PJ, Lown B. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. American Journal of Cardiology 61: 349–353, 1988
Stanton MS, Prystowsky EN, Fineberg NS, Miles WM, Zipes DP, et al. Incidence of ventricular tachycardia or ventricular fibrillation as proarrhythmic effects during drug treatment of ventricular arrhythmia. Abstract. Journal of the American College of Cardiology 9: 245A, 1987
Story JR, Abdulla AM, Frank MJ. Cardiogenic shock and disopyramide phosphate. Journal of the American Medical Association 242: 654–655, 1979
Strasberg B, Sclarovsky S, Erdberg A, Duffy CE, Lam W, et al. Procainamide-induced polymorphous ventricular tachycardia. American Journal of Cardiology 47: 1309–1314, 1981
Sukenik S, Horowitz J, Katz A, Henkin J, Buskila D. Quinidineinduced lupus erythematosus-like syndrome: three case reports and a review of the literature. Israel Journal of Medical Sciences 23: 1232–1234, 1987
Swiryn S, Kim SS. Quinidine-induced syncope. Archives of Internal Medicine 143: 314–316, 1983
Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, et al. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. Journal of the American College of Cardiology 10: 633–641, 1987
Thompson KA, Murray JJ, Blair IA, Woosley RL, Roden DM. Plasma concentrations of quinidine, its major metabolites and dihydroquinidine in patients with torsades de pointes. Clinical Pharmacology and Therapeutics 43: 636–642, 1988
Torok E, Bajkay G, Gulyas A, Maklary E. Comparative study of a long-acting quinidine preparation and quinidine sulfate in chronic atrial fibrillation. Pharmacologia Clinica 2: 90–93, 1970
Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-2B with symptomatic procainamide-induced lupus. New England Journal of Medicine 318: 1431–1436, 1988
Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 77: 392–397, 1988
Ueda CT, Hirschfeld DS, Scheinman MM, Rowland M, Williamson BJ, et al. Disposition kinetics of quinidine. Clinical Pharmacology and Therapeutics 19: 30–36, 1976b
Ueda CT, Williamson BJ, Dzindzio BS. Absolute quinidine bioavailability. Clinical Pharmacology and Therapeutics 20: 260–265, 1976a
VanderArk CR, Reynolds EW, Kahn DR, Tullett G. Quinidine syncope: a report of successful treatment with bretylium tosylate. Journal of Thoracic and Cardiovascular Surgery 72: 464–467, 1976
Viko LE, Marvin HM, White PD. Clinical report of the use of quinidine sulfate. Archives of Internal Medicine 31: 345–363, 1923
Villalba-Pimentel L, Epstein LM, Sellers EM, Foster JR, Bennion LJ, et al. Survival after massive procainamide ingestion. American Journal of Cardiology 32: 727–730, 1973
Vlasses PH, Ferguson RK, Rocci ML, Raja RM, Porter RS, et al. Lethal accumulation of procainamide metabolite in severe renal insufficiency. American Journal of Nephrology 6: 112–116, 1986
Vlasses PH, Kosoglou T, Chase SL, Greenspon AJ, Lottes S, et al. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Archives of Internal Medicine 149: 1350–1353, 1989
Vozeh S, Uematsu T, Guentert TW, Ha HR, Follath F. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. Clinical Pharmacology and Therapeutics 37: 575–581, 1985
Vozeh S, Oti-Amoako K, Uematsu T, Follath F. Antiarrhythmic activity of two quinidine metabolites in experimental reperfusion arrhythmia: relative potency and pharmacodynamic interaction with the parent drug. Journal of Pharmacology and Experimental Therapeutics 243: 297–301, 1987
Wasserman F, Brodsky L, Dick MM, Kathe JH, Rodensky PL. Successful treatment of quinidine and procaine amide intoxication. Report of three cases. New England Journal of Medicine 259: 797–802, 1958
Wayne K, Manolas E, Sloman G. Fatal overdose with disopyramide. Medical Journal of Australia 1: 231–232, 1980
Weisbart RH, Yee WS, Colburn KK, Whang SH, Heng MK, et al. Antiguanosine antibodies: a new marker for procainamideinduced systemic lupus erythematosus. Annals of Internal Medicine 104: 310–313, 1986
Wellens HJJ. Value and limitations of programmed electrical stimulation of the heart in the study and treatment of tachycardias. Circulation 57: 845–853, 1978
Whiting B, Elliott HL. Disopyramide in renal impairment. Lancet 2: 1363, 1977
Woie L, Oyri A. Quinidine intoxication treated with hemodialysis. Acta Medica Scandinavica 195: 237–239, 1974
Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. New England Journal of Medicine 298: 1157–1159, 1978
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kim, S.Y., Benowitz, N.L. Poisoning Due to Class IA Antiarrhythmic Drugs. Drug-Safety 5, 393–420 (1990). https://doi.org/10.2165/00002018-199005060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199005060-00002